



April 28, 2017

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Mr. Jiten Patel,

In response to your mail dated April 28, 2017, in connection with the news item appearing in today's Business Standard titled 'Lupin Goa plant receives adverse FDA observations', we offer our comments as under: -

Recently, the Company's Goa manufacturing facility underwent an inspection by the US FDA. The said inspection was completed on April, 7, 2017, subsequent to which, the US FDA issued Form-483 citing three observations. We are in the midst of putting together a response to address the said observations.

We wish to state that the Company has multiple facilities which cater to the US and other advanced markets and undergo periodic routine inspections by the US FDA or other regulators from different countries, in the normal course of business.

We wish to inform you that the Company promptly discloses to the BSE Limited and National Stock Exchange of India Limited, information required to be disclosed under Regulation 30 of the 'Listing Regulations'. If there is any material development related to the said inspection, we will promptly inform the Stock Exchanges.

Hope we have clarified the matter.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**


R. V. SATAM
COMPANY SECRETARY

